|
US2015342871A1
|
|
Highly permeating terbinafine formulation
|
|
US2016279245A1
|
|
Topical formulations, systems, and methods
|
|
US2013337031A1
|
|
Topical formulations, systems and methods
|
|
US2014026905A1
|
|
Apparatus and method of controlling the rate of nicotine delivery
|
|
US2013065870A1
|
|
Treatment of pain with topical diclofenac
|
|
US2014113970A1
|
|
Dispensing system
|
|
EP2575813A1
|
|
Topical etoricoxib formulation
|
|
AU2011248162A1
|
|
Triamcinolone acetonide formulations for treating dermatitis and psoriasis
|
|
WO2011112875A2
|
|
Foamable formulation
|
|
AU2011205730A1
|
|
Solid-forming local anesthetic formulations for pain control
|
|
CN102770123A
|
|
Highly permeating terbinafine formulation for treating onychomycosis
|
|
BR112012012789A2
|
|
topical ibuprofen formulations
|
|
EP2498819A2
|
|
Topical etoricoxib formulation comprsing an eutectic mixture of permeation enhancers
|
|
EP2485730A1
|
|
Topical formulation comprising etoricoxib and a zwitterionic surfactant
|
|
EP2482850A2
|
|
Topical formulations
|
|
CA2805749A1
|
|
Pharmaceutical formulations and methods of use
|
|
US2011028460A1
|
|
Topical formulation
|
|
EP2349337A1
|
|
Formulations for the treatment of acute herpes zoster pain
|
|
CN104606126A
|
|
Diclofenac gel
|
|
WO2007098591A2
|
|
Topical nail formulation
|
